Biofrontera received official review of its drug approval dossier for BF-200 ALA

23-Dec-2010 - Germany

Biofrontera announces that the European Medical Agency (EMA) has sent the official summaries and preliminary questions of the reviewers (rapporteurs) about the approval dossier of its leading drug candidate BF-200 ALA for actinic keratosis. The reviews will now be distributed to all member states of the EU. Major objections were neither raised in the preclinical nor the clinical part of the dossier. Contingent on satisfactory answers to the questions raised, the rapporteur recommended the drug approval.

According to the current understanding of Biofrontera management, the reviews are in line with the current temporal and financial planning. Thus, market introduction is still expected for the fall of 2011.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Cancer identity technology makes it easier to find a tumor's 'address'

Cancer identity technology makes it easier to find a tumor's 'address'

MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer

Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals - New, scalable population of hemangioblast cells halves the death rate following heart attack and repairs ischemic limbs and damaged vasculature

AlyXan - Juvisy-sur-Orge, France

AlyXan - Juvisy-sur-Orge, France

Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program - Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds

How does the brain in schizophrenia work?

Interpharma - Verband der forschenden pharmazeutischen Firmen der Schweiz - Basel, Switzerland

Interpharma - Verband der forschenden pharmazeutischen Firmen der Schweiz - Basel, Switzerland

NYU Langone Medical Center and School of Medicine - New York City, USA

New version of common antibiotic could eliminate risk of hearing loss

Nanovectors Could Improve the Combined Administration of Antimalarial Drugs - According to the study, the strategy has the added advantage of targeting the transmissible phase of the parasite- the gametocyte

Nanovectors Could Improve the Combined Administration of Antimalarial Drugs - According to the study, the strategy has the added advantage of targeting the transmissible phase of the parasite- the gametocyte

Fahr's_disease

NHM scientists discover first-ever mineral-based treatment for widespread disease using the structure of crystals - Based on the structure of cubic zirconium silicate, the innovative treatment opens doors to future mineral-based treatments made possible by cutting-edge museum science

NHM scientists discover first-ever mineral-based treatment for widespread disease using the structure of crystals - Based on the structure of cubic zirconium silicate, the innovative treatment opens doors to future mineral-based treatments made possible by cutting-edge museum science